Vitamin D treatment and mortality in chronic kidney disease: A systematic review and meta-analysis

American Journal of Nephrology

Volumn 37, Issue 3, 2013, Pages 239-248

  Duranton, Flore ^a   Rodriguez Ortiz, Maria E ^b   Duny, Yohan ^a   Rodriguez, Mariano ^b   Daurès, Jean Pierre ^a   Argilés, Angel ^a  

^a UNIV MONTPELLIER   (France)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Cardiovascular mortality; Chronic kidney disease; Mortality; Survival; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; CALCITRIOL; DOXERCALCIFEROL; PARICALCITOL; PLACEBO; VITAMIN D; VITAMIN D DERIVATIVE; PARATHYROID HORMONE;

ARTICLE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; HUMAN; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMATIC REVIEW; CARDIOVASCULAR RISK; EFFECT SIZE; HEMODIALYSIS PATIENT; META ANALYSIS; PARATHYROID HORMONE BLOOD LEVEL; POPULATION SIZE; PRESCRIPTION; RISK FACTOR; TREATMENT DURATION;

CALCITRIOL; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84874625616     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000346846     Document Type: Article

References (49)

1. Wang TJ, Pencina MJ, Booth SL, et al: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511.
2. Melamed ML, Michos ED, Post W, Astor B: 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1630.
3. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S: Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011; 58: 374-382.
4. Rojas-Rivera J, De La Piedra C, Ramos A, Ortiz A, Egido J: The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 2010; 25: 2850-2865.
5. Autier P, Gandini S: Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730-1737.
6. Massry S: K DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S16.
7. Ravani P, Malberti F, Tripepi G, et al: Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75: 88-95.
8. Kandula P, Dobre M, Schold JD, et al: Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6: 50-62.
9. Argiles A, Lorho R, Mourad G, Mion CM: High-dose alfacalcidol for anaemia in dialysis. Lancet 1993; 342: 378-379.
10. Argiles A, Mourad G, Lorho R, et al: Medical treatment of severe hyperparathyroidism and its influence on anaemia in end-stage renal failure. Nephrol Dial Transplant 1994; 9: 1809-1812.
11. Palmer SC, McGregor DO, Macaskill P, et al: Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147: 840-853.
12. Park CW, Oh YS, Shin YS, et al: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81.
13. Wolf M, Shah A, Gutierrez O, et al: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
14. Rostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383-392.
15. Tian J, Liu Y, Williams LA, de Zeeuw D: Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 2007; 22: 321-328.
16. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
17. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
18. Parmar MKB, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
19. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
20. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. Brit Med J 1997; 315: 629-634.
21. Duval S, Tweedie R: Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463.
22. Orwin RG: A fail-safe N for effect size in metaanalysis. J Educ Behav Stat 1983; 8: 157-159.
23. Shinaberger CS, Kopple JD, Kovesdy CP, et al: Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1769-1776.
24. St Peter WL, Li S, Liu J, et al: Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis. Pharmacotherapy 2009; 29: 154-164.
25. Kalantar-Zadeh K, Miller JE, Kovesdy CP, et al: Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D and survival in hemodialysis patients. J Bone Miner Res 2010; 25: 2724-2734.
26. Jean G, Lataillade D, Genet L, et al: Impact of hypovitaminosis D and alfacalcidol therapy on survival of hemodialysis patients: results from the French ARNOS study. Nephron Clin Pract 2011; 118:c204-c210.
27. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
28. Lee GH, Benner D, Regidor DL, Kalantar-Zadeh K: Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr 2007; 17: 38-44.
29. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403.
30. Marco MP, Craver L, Betriu A, et al: Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl 2003; 63:S111-S114.
31. Melamed ML, Eustace JA, Plantinga L, et al: Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357.
32. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al: Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078.
33. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619.
34. Shoji T, Shinohara K, Kimoto E, et al: Lower risk for cardiovascular mortality in oral 1α-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184.
35. Sugiura S, Inaguma D, Kitagawa A, et al: Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol 2010; 14: 43-50.
36. Taniguchi M, Yamada S, Tokumoto M, Tsuruya K, Hirakata HN: Active vitamin D therapy is associated with lower mortality, especially in low 25(OH)D levels. Renal Week 2010, Abstract Sessions, 2010 TH-PO199. http://www.asn-online.org/ education-and-meetings/kidneyweek/archives/RW10Abstracts.pdf (accessed January 25, 2012).
37. Teng M, Wolf M, Ofsthun MN, et al: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
38. Tentori F, Hunt WC, Stidley CA, et al: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865.
39. Tentori F, Albert JM, Young EW, et al: The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24: 963-972.
40. Wolf M, Betancourt J, Chang Y, et al: Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008; 19: 1379-1388.
41. Olgaard K, Lewin E: Use (or misuse) of vitamin D treatment in CKD and dialysis patients. Nephrol Dial Transplant 2008; 23: 1786-1789.
42. Palmer SC, McGregor DO, Craig JC, et al: Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; CD008175.
43. Palmer SC, McGregor DO, Craig JC, et al: Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 2009; CD005633.
44. Block GA, Klassen PS, Lazarus JM, et al: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
45. Cheng J, Zhang W, Zhang X, Li X, Chen J: Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2012; 7: 391-400.
46. Reeves BC, Deeks JJ, Higgins JPT, Wells GA: Chapter 13: Including non-randomized studies; in Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1. Chichester, The Cochrane Collaboration, John Wiley & Sons Ltd., 2008, pp 391-432.
47. Cox E, Martin BC, Van Staa T, et al: Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources. Value Health 2009; 12: 1053-1061.
48. EVOLVE Trial Investigators: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. New Engl J Med 2012; 367: 2482-2494.
49. Thadhani R, Appelbaum E, Pritchett Y, et al: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: 674-684.